Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: A new mechanism linking berberine to insulin resistance improvement - PubMed (original) (raw)
doi: 10.1016/j.biopha.2017.03.003. Epub 2017 Mar 6.
Lili Feng 1, Fang Xu 1, Yi Sun 1, Yuxiang Ma 1, Xiong Zhang 1, Hailiang Liu 1, Ge Xu 1, Xuefeng Wu 1, Yan Shen 1, Yang Sun 1, Xudong Wu 2, Qiang Xu 3
Affiliations
- PMID: 28282788
- DOI: 10.1016/j.biopha.2017.03.003
Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: A new mechanism linking berberine to insulin resistance improvement
Hang Zhou et al. Biomed Pharmacother. 2017 May.
Abstract
NLRP3 (Nod-like receptor family pyrin domain containing 3) inflammasome has been reported to contribute to obesity-induced inflammation and insulin resistance. However, there are few drugs targeting NLRP3 inflammasome for the treatment of insulin resistance. In the present study, we showed that berberine (BBR) significantly suppressed saturated fatty acid palmitate (PA)-induced NLRP3 inflammasome activation and interleukin-1β (IL-1β) release in macrophages, which was one of the most important mediators in the insulin sensitivity of adipose tissue. BBR treatment dramatically upregulated macrophage autophagic level while knockdown beclin1 and autophagy inhibitor reversed BBR's suppression on inflammasome. Furthermore, AMPK (adenosine monophosphate-activated protein kinase) inhibitor Adenine 9-β-d-arabinofuranoside (Ara-A) blocked most effects of BBR, suggesting that AMPK signals may be involved in BBR-induced macrophage autophagy. Importantly, BBR also prevented NLRP3 inflammasome-dependent inflammation and metabolic disorder in a high-fat-diet-induced insulin resistance model. Adoptive transfer of BBR-treated bone marrow-derived macrophages (BMDMs), which was induced by lipopolysaccharide (LPS) plus palmitate-bovine serum albumin (PA-BSA), significantly ameliorated insulin resistance of ob/ob mice as compared with control mice. However, the co-treatment of the BMDMs with autophagy inhibitor 3-Methyladenine (3-MA) reversed the effect of BBR almost completely. Taken together, BBR exerted its anti-inflammatory effects through activation of AMPK-dependent autophagy in adipose tissue macrophages (ATMs). This study amplified the mechanisms of BBR and its potential in attenuating insulin resistance.
Keywords: Adipose tissue macrophages; Autophagy; Berberine; Insulin resistance; NLRP3 inflammasome.
Copyright © 2017. Published by Elsevier Masson SAS.
Similar articles
- Berberine suppresses influenza virus-triggered NLRP3 inflammasome activation in macrophages by inducing mitophagy and decreasing mitochondrial ROS.
Liu H, You L, Wu J, Zhao M, Guo R, Zhang H, Su R, Mao Q, Deng D, Hao Y. Liu H, et al. J Leukoc Biol. 2020 Jul;108(1):253-266. doi: 10.1002/JLB.3MA0320-358RR. Epub 2020 Apr 9. J Leukoc Biol. 2020. PMID: 32272506 - Chikusetsu saponin IVa ameliorates high fat diet-induced inflammation in adipose tissue of mice through inhibition of NLRP3 inflammasome activation and NF-κB signaling.
Yuan C, Liu C, Wang T, He Y, Zhou Z, Dun Y, Zhao H, Ren D, Wang J, Zhang C, Yuan D. Yuan C, et al. Oncotarget. 2017 May 9;8(19):31023-31040. doi: 10.18632/oncotarget.16052. Oncotarget. 2017. PMID: 28415686 Free PMC article. - Berberine inhibits NLRP3 inflammasome activation and proinflammatory macrophage M1 polarization to accelerate peripheral nerve regeneration.
Sun J, Zeng Q, Wu Z, Huang L, Sun T, Ling C, Zhang B, Chen C, Wang H. Sun J, et al. Neurotherapeutics. 2024 Jul;21(4):e00347. doi: 10.1016/j.neurot.2024.e00347. Epub 2024 Apr 3. Neurotherapeutics. 2024. PMID: 38570276 Free PMC article. - NLRP3 Inflammasome Activation in Adipose Tissues and Its Implications on Metabolic Diseases.
Wu KK, Cheung SW, Cheng KK. Wu KK, et al. Int J Mol Sci. 2020 Jun 11;21(11):4184. doi: 10.3390/ijms21114184. Int J Mol Sci. 2020. PMID: 32545355 Free PMC article. Review. - The NLRP3 inflammasome regulates adipose tissue metabolism.
Barra NG, Henriksbo BD, Anhê FF, Schertzer JD. Barra NG, et al. Biochem J. 2020 Mar 27;477(6):1089-1107. doi: 10.1042/BCJ20190472. Biochem J. 2020. PMID: 32202638 Review.
Cited by
- A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study.
Wang ZZ, Li K, Maskey AR, Huang W, Toutov AA, Yang N, Srivastava K, Geliebter J, Tiwari R, Miao M, Li XM. Wang ZZ, et al. FASEB J. 2021 Apr;35(4):e21360. doi: 10.1096/fj.202001792R. FASEB J. 2021. PMID: 33749932 Free PMC article. - Research Progress on Antibacterial Activities and Mechanisms of Natural Alkaloids: A Review.
Yan Y, Li X, Zhang C, Lv L, Gao B, Li M. Yan Y, et al. Antibiotics (Basel). 2021 Mar 19;10(3):318. doi: 10.3390/antibiotics10030318. Antibiotics (Basel). 2021. PMID: 33808601 Free PMC article. Review. - Berberine inhibits NLRP3 Inflammasome pathway in human triple-negative breast cancer MDA-MB-231 cell.
Yao M, Fan X, Yuan B, Takagi N, Liu S, Han X, Ren J, Liu J. Yao M, et al. BMC Complement Altern Med. 2019 Aug 14;19(1):216. doi: 10.1186/s12906-019-2615-4. BMC Complement Altern Med. 2019. PMID: 31412862 Free PMC article. - Natural biomolecules and derivatives as anticancer immunomodulatory agents.
Bernitsa S, Dayan R, Stephanou A, Tzvetanova ID, Patrikios IS. Bernitsa S, et al. Front Immunol. 2023 Jan 9;13:1070367. doi: 10.3389/fimmu.2022.1070367. eCollection 2022. Front Immunol. 2023. PMID: 36700235 Free PMC article. Review. - Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis.
Yang L, Zhang X, Wang Q. Yang L, et al. Front Endocrinol (Lausanne). 2022 Dec 15;13:992937. doi: 10.3389/fendo.2022.992937. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36589841 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous